A new study published on medRxiv reveals that masitinib treatment in ALS patients significantly improves survival rates, with a 5-year survival rate of 42.3%, doubling historical benchmarks. The study highlights that early intervention leads to even better outcomes, with 52.9% survival in patients without prior complete loss of functionality. Nearly half of long-term survivors maintained good quality of life without mechanical assistance. These findings suggest masitinib's potential as a neuroprotective therapy targeting microglial and mast cell activity, with ongoing trials aiming to confirm efficacy and identify responsive patient subpopulations.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
Bitcoin Treasury Capital, a Stockholm-based firm, has received approval to issue 195,078 Class A preferred shares on the Spotlight Stock Market, starting July 20, 2026. These shares, priced at SEK 120 each, offer a 10% annual dividend backed entirely...
Bitcoin price recently hit a strong resistance level at $65,600 but failed to break through, signaling a possible reversal. Short-term momentum is weakening, suggesting the price may decline unless a sudden surge occurs. Key support levels include th...
